Bioengineered Bile Duct for Liver Regenerative Medicine and Bile Duct Reconstruction
- PMID: 40809896
- PMCID: PMC12343205
- DOI: 10.1002/jgh3.70254
Bioengineered Bile Duct for Liver Regenerative Medicine and Bile Duct Reconstruction
Abstract
Bioengineered tubular bile ducts are an emerging strategy in liver regenerative medicine and extrahepatic bile duct reconstruction, offering potential solutions to address biliary diseases and improve outcomes in liver transplantation. Disorders of the biliary system, such as biliary atresia, primary sclerosing cholangitis, and bile duct injury, often result in irreversible damage and cannot be adequately treated with conventional therapies. This review explores the latest advancements in the bioengineering of both intrahepatic and extrahepatic bile ducts, focusing on approaches that leverage cholangiocyte biology, stem cell technologies, and biomaterial innovations. Key cell sources, including primary cholangiocytes, induced pluripotent stem cells (iPSCs), liver progenitor cells (LPCs), and transdifferentiated hepatocytes, are discussed for their potential to generate functional bile duct epithelial cells capable of restoring biliary function. The role of biomaterials in providing structural support and promoting cellular growth and differentiation is critically examined, emphasizing synthetic and natural scaffolds, such as poly(lactic acid) (PLA) and collagen-based materials, for creating viable tubular structures. This review provides a comprehensive overview of the current progress and challenges in bioengineered bile duct tissue, focusing on the goals of enhancing liver regeneration and enabling extrahepatic bile duct reconstruction for clinical applications. Integrating cellular, biomaterial, and bioengineered strategies offers promising avenues for advancing treatments for biliary diseases and improving liver transplantation outcomes.
Keywords: bioartificial; bioengineered bile duct; biomaterials; cholangiopathies; liver regeneration.
© 2025 The Author(s). JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Biliary atresia susceptibility gene EFEMP1 regulates extrahepatic bile duct elastic fiber formation and mechanics.JHEP Rep. 2024 Sep 8;7(1):101215. doi: 10.1016/j.jhepr.2024.101215. eCollection 2025 Jan. JHEP Rep. 2024. PMID: 39717503 Free PMC article.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Microcystin-RR is a biliary toxin selective for neonatal extrahepatic cholangiocytes.JHEP Rep. 2024 Sep 12;7(1):101218. doi: 10.1016/j.jhepr.2024.101218. eCollection 2025 Jan. JHEP Rep. 2024. PMID: 39687604 Free PMC article.
-
Advances in Regenerative Medicine, Cell Therapy, and 3D Bioprinting for Corneal, Oculoplastic, and Orbital Surgery.Adv Exp Med Biol. 2025;1483:69-114. doi: 10.1007/5584_2025_855. Adv Exp Med Biol. 2025. PMID: 40131704 Review.
-
Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011648. doi: 10.1002/14651858.CD011648.pub2. Cochrane Database Syst Rev. 2017. PMID: 28350426 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources